The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
本发明涉及新化合物,以及用于它们的制备方法,它们在治疗中的应用以及包含这些新化合物的药物组合物。
POLYCYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF THE METABOTROPIC GLUTAMATE 5 RECEPTOR
申请人:AstraZeneca AB
公开号:EP2032568A2
公开(公告)日:2009-03-11
US7678796B2
申请人:——
公开号:US7678796B2
公开(公告)日:2010-03-16
[EN] MGLUR5 MODULATORS IV<br/>[FR] MODULATEURS DES RÉCEPTEURS MGLUR5 IV
申请人:ASTRAZENECA AB
公开号:WO2007130823A2
公开(公告)日:2007-11-15
[EN] The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds. [FR] La présente invention concerne de nouveaux composés, un processus de préparation de ceux-ci et leur utilisation thérapeutique ainsi que des compositions pharmaceutiques comprenant ces nouveaux composés.
MGluR5 modulators IV
申请人:Isaac Methvin
公开号:US20070259923A1
公开(公告)日:2007-11-08
The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.